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https://doi.org/10.1016/j.celrep.2020.108171SUMMARYHigh-risk neuroblastomas typically display an undifferentiated or poorly differentiated morphology. It is
therefore vital to understand molecular mechanisms that block the differentiation process. We identify an
important role for oncogenic ALK-ERK1/2-SP1 signaling in the maintenance of undifferentiated neural
crest-derived progenitors through the repression of DLG2, a candidate tumor suppressor gene in neuroblas-
toma. DLG2 is expressed in the murine ‘‘bridge signature’’ that represents the transcriptional transition state
when neural crest cells or Schwann cell precursors differentiate to chromaffin cells of the adrenal gland. We
show that the restoration of DLG2 expression spontaneously drives neuroblastoma cell differentiation, high-
lighting the importance of DLG2 in this process. These findings are supported by genetic analyses of high-
risk 11q deletion neuroblastomas, which identified genetic lesions in the DLG2 gene. Our data also suggest
that further exploration of other bridge genes may help elucidate the mechanisms underlying the differenti-
ation of NC-derived progenitors and their contribution to neuroblastomas.INTRODUCTION
Pediatric neuroblastoma (NB) is a heterogeneous disease, with
differing prognosis depending on the subgroup. Some cases un-
dergo spontaneous differentiation or regression with little or no
therapy, while cases classified as high-risk NB have a decreased
response rate to standard therapeutic regimens and relapse with
an overall survival rate of <40% at 5 years (Maris, 2010; Maris
et al., 2007).NB is characterizedbymultiple somatic chromosomal
lesions at the genetic level, including structural variations (SVs) and
copy-number alterations (CNAs). Relatively few mutations are de-
tected in NB in comparison to other cancer types (De Brouwer
et al., 2010; Gro¨bner et al., 2018; Pugh et al., 2013). The commonCel
This is an open access article undgenetic features of NB include deletion of chromosome arm 1p,
gain of parts of 17q, aneuploidy and amplification of the proto-
oncogeneMYCN, and deletion of parts of chromosome arm 11q,
which are used to distinguish between high- and low-risk NB (Bro-
deur,2003;Care´netal., 2008,2010;DeBrouweretal., 2010;Hoeh-
ner et al., 1996; Maris, 2010; Park et al., 2013; Pugh et al., 2013).
Previous studies have reported 11q deletions (11q del) in 43% of
cases, suggesting this to be the most common deletion observed
in NB tumors. Although unbalanced chromosomal alterations
affecting 11q have been known for some time, no single candidate
gene has been confirmed to play a role in NB despite intensive
investigation, including thorough deletion mapping of this crucial
region (11q14–q24) (Care´netal., 2008,2010;Srivatsanetal., 1993).l Reports 32, 108171, September 22, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. The Bridge Gene DLG2 Suppresses NB Tumorigenic Growth
(A) Schematic overview of the transcription-based hypothesis outlining the differentiation trajectory of SCPs toward adrenal chromaffin fate (Furlan et al., 2017).
SCPs, Schwann cell precursors (yellow); bridge cells (red), chromaffin cells (brown).
(B–D) Logistic regression analysis of the expected effect of bridge gene expression on prognosis as a function of peak expression pseudotime (B). The graph
shows a regression line, with the 95% confidence interval indicated by the gray area. The dots represent bridge genes with either a positive (upper dots) or a
negative (lower dots) correlation between expression and prognosis, as derived from the R2 platform (Kocak dataset, KaplanScan method) and illustrated (C) for
DLG2 and (D) ASCL1 by the survival plots on the right. The bridge gene and pseudotime data were derived from Furlan et al. (2017). Only bridge genes that were
unambiguously mapped from mouse to human gene names were used for the analysis.
(E and F) Western blot confirmation of DLG2-GFP overexpression in SK-N-AS and SH-SY5Y cells.
(legend continued on next page)
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OPEN ACCESSIn recent years, our understanding of the underlying develop-
mental processes involved in NB has increased. NB is
considered an embryonal malignancy of the sympathetic ner-
vous system that develops from un-differentiated neural crest-
derived cells (NCCs), arising in the adrenal medulla and the sym-
pathetic ganglia (Huber et al., 2009; Saito et al., 2012). NCCs
arise at mid-gestation around the closure of the neural tube.
Subsequently, NCCs undergo migration, ultimately generating
a variety of tissues. In the sympathoadrenal (SA) lineage, NCCs
reach their destinations close to the dorsal aorta, where they pro-
liferate, differentiate into neurons and glia, and finally form the
sympathetic ganglia and the chromaffin cells that contribute to
the adrenal medulla. Recently, it was reported that the majority
of chromaffin cells in the adrenal medulla arise from peripheral
stem cells called Schwann cell precursors (SCPs) (Furlan et al.,
2017). SCPsmigrate along the visceral motor nerves to the vicin-
ity of the developing adrenal gland and form postsynaptic neuro-
endocrine chromaffin cells.
During development, the adrenal medulla is thought to be
generated from both neural crest SA lineage cell precursors
and SCPs, with SA lineage cell precursors destined to become
sympathetic neurons or chromaffin cells and SCPs destined to
become chromaffin cells (Furlan et al., 2017). In their study, Fur-
lan and coworkers examined the transcriptional transition from
SCPs to chromaffin cells and revealed a transient cellular state
connecting both SCPs and chromaffin cells, identifiable by a
transcriptional pattern, which they called the bridge signature.
In this signature, they identified SCP-specific genes that were
downregulated and upregulated in cells undergoing differentia-
tion to an adrenergic (ADRN) chromaffin fate (Furlan et al.,
2017). Loss of differentiation is a hallmark of high-risk NB, and
loss of key differentiation factors potentially affect NB progres-
sion, highlighted by the presence of PHOX2B in the bridge signa-
ture. Furthermore, there are well-established genetic mutations
in several loci that are associated with development of NB,
including ALK, PTPN11, and ATRX (Pugh et al., 2013). Recently,
it was observed that the expression of ALK-F1174L gain-of-
function mutation during embryogenesis impairs the differentia-
tion of neural crest progenitors in sympathetic ganglia (Vivancos
Stalin et al., 2019). In addition, NB tumors with evidence of high
ALK or MYCN protein expression exhibit undifferentiated or
poorly differentiated histology (Chang et al., 2020). Since many
cases of low-risk NB either differentiate or regress, there is
much interest in identifying differentiation-inducing mechanisms
for NB. One identified factor that induces differentiation is reti-
noic acid (RA), which is used clinically and improves event-free
survival (Brodeur and Bagatell, 2014; de The´, 2018; Matthay
et al., 1999).
Based on our current understanding of NB, we hypothesized
that genes included in the bridge signature may contribute to(G–I) Rate of cell growth in cells expressing DLG2was determined by scanning live
DLG2-GFP) in (G), SH-SY5Y (GFP or DLG2-GFP) in (H), and SK-N-BE(2) (GFP or
(J and K) The effect of DLG2 overexpression on cell cycle in SK-N-AS (GFP or D
(L and M) Tumor growth (L) weight (box and whiskers plot, M) of SK-N-AS-DLG2
[DLG2]). Multiple t test (for proliferation, tumor volume, and migration data) or un
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Quantified data are meanNB progression. To understand this better, we investigated the
relationship between the expression of the individual bridge
genes and NB prognosis. This in silico analysis also suggested
the Disks Large Homolog 2 (DLG2) gene as a strong candidate
that may play a role in differentiation in an NB context. Subse-
quent biochemical, in vitro, and in vivo analyses identified
DLG2 protein as a critical determinant of differentiation in NB
cells. When combined with differentiation-promoting factors
such as RA or nerve growth factor (NGF), DLG2 expression re-
sulted in almost complete differentiation of NB cells. In keeping
with this function, we also show that DLG2 levels are highly sen-
sitive to ALK pathway activity, and in differentiation-poor ALK-
driven NB DLG2 expression is suppressed, allowing ALK to pro-
mote an undifferentiated NB state. A role for DLG2 as a tumor
suppressor gene is supported by genetic analysis of NB patient
material that identifies genetic lesions at 11q mapping at high
frequency to the DLG2 gene. Our results identify DLG2 as a tu-
mor suppressor in NB that plays a critical role in the differentia-
tion of neural crest lineages.
RESULTS
Genes Expressed during SCP to Chromaffin Cell
Differentiation Are Prognostic of NB Patient Outcome
NB is considered a disease of failed differentiation of neural
crest-derived progenitors such as SCPs and sympathoadrenal
precursor cells. Furlan et al. (2017) identified a unique set of mu-
rine genes expressed by transient intermediate cells they called
bridge cells that arise during the differentiation of SCPs to adre-
nal chromaffin cells (Figure 1A). Since ~50% of NB arises in the
adrenal gland, we hypothesized that the deregulation of genes
and signaling pathways in the bridge cells could block progenitor
cell differentiation. We further hypothesized that genes that are
uniquely downregulated or upregulated in the bridge cells could
be anti- or pro-differentiation, respectively (Figure 1A). Hence,
high expression of genes that are up- or downregulated in the
bridge cells may promote undifferentiated (poor prognosis) or
differentiated (good prognosis) NB phenotypes, respectively
(Figure 1A). To examine whether the temporal order of this regu-
lation of murine bridge cell genes is associated with human NB
tumor biology and patient outcome, we used the R2:genomics
analysis and visualization platform (https://hgserver1.amc.
nl:443/) to investigate their correlation with NB prognosis (Kocak
NB dataset; 649 tumors). The high overall expression of early
peak time bridge cell genes in NB patient tumor material strongly
correlated with poor prognosis, while high expression of late
peak time bridge cell genes correlated with better prognosis (lo-
gistic regression p = 0.0019; Figures 1B–1D). A number of these
genes have already been reported to play roles in NB pathogen-
esis, such as ASCL1 (Figure 1D) (Kasim et al., 2016), PHOX2B-cell confluency in an IncuCyte S3 at 12-h intervals for 5 days. SK-N-AS (GFP or
DLG2-GFP) in (I). Growth curves plotted with GraphPad Prism version 8.01.
LG2-GFP) (J) and SH-SY5Y (GFP or DLG2-GFP) (K) cells.
and SK-N-AS-GFP controls in a NB xenograft mice model (n = 10 [ctrl], n = 9
paired t test (for others).
s ± SDs of at least 3 independent experiments. AU, arbitrary unit.
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et al., 2017), SOX2 (Yang et al., 2015), IGFBP2 (Russo et al.,
2005), and ID2 (Wieczorek and Balwierz, 2015). However,
many genes from the bridge cell signature, including DLGAP2,
IGSF21, ADAMTS19, DLG2, and TMEM179, are regulated in
the developmental timeline toward the chromaffin phenotype
and have not been functionally investigated in NB. We hypothe-
sized that the deregulation of these genes may play a role in NB
progression.
Two genes of particular interest were DLG2 and DLGAP2. The
latter encodes a protein that has been shown to interact with
DLG2 (Marshall et al., 2008). Earlier observations indicate that
both DLG2 and DLGAP2 play a role in themolecular organization
of synapse and neuronal signaling (Marshall et al., 2008). In the
bridge signature, DLG2 and DLGAP2 are upregulated in the final
steps of SCP to chromaffin cell differentiation (Figure 1B) (Furlan
et al., 2017).
The DLG2 gene encodes postsynaptic density protein 93
(PSD93), a protein belonging to the family of molecular scaf-
folding proteins known as membrane-associated guanylate ki-
nases, or MAGUKs. A core of three disparate domains, including
a guanylate kinase domain, an SH3 domain, and three PDZ do-
mains interacting with each other, defines members of this pro-
tein family (Roberts et al., 2012). The DLG2 homolog in
Drosophila, Dlg, is a well-characterized tumor suppressor,
which, when mutated, results in neoplastic overgrowth of the
Drosophila imaginal discs (Woods and Bryant, 1991). Recently,
DLG2 has been reported as a tumor suppressor in both dog
and human osteosarcomas (Shao et al., 2019). High DLG2 levels
correlate with better prognosis and event-free survival in NB pa-
tients (https://hgserver1.amc.nl:443/). This correlation was
observed in four different NB patient datasets, using two
different cutoff methods (Figures 1C and S1). DLG2 lies on chro-
mosome 11q, which is widely known as a high-risk deletion re-
gion in NB (Care´n et al., 2008, 2010; Fieuw et al., 2012; Maris
et al., 2001; Spitz et al., 2003; Srivatsan et al., 1993). Since a
role for DLG2 in NB has not been described, we decided to
investigate (1) its importance in the differentiation of NB cells
and (2) the putative tumor suppression function of DLG2 in NB.DLG2 Overexpression Potently Inhibits Tumorigenic
Phenotypes of NB Cells In Vitro
To investigate whether restoring DLG2 expression affected the
tumorigenic properties of NB cells, we established stable,
constitutive DLG2 expression in SK-N-AS, SH-SY5Y, and SK-
N-BE(2) NB cell lines using a lentivirus-based expression system
(Figures 1E, 1F, and S2F). The SK-N-AS cell line harbors an
NRASQ61R mutation with an 11q-deletion, SH-SY5Y harbors anFigure 2. Ectopic DLG2 Expression Induces Neuronal Differentiation
(A–C) Representative images showing morphological differentiation of NB cells u
cells) or 48 h (for SK-N-SH and SK-N-BE(2) cells). SH-SY5Y (GFP or DLG2-GFP) (
(D–F) Bar charts showing percentage differentiation of respective NB cells follow
(G–I) Western blot showing the effect of DLG2 overexpression and RA on expre
denotes the endogenous DLG2 protein.
(J–M) Effect of doxycycline (Dox)-inducible shRNA-mediated DLG2 knockdown in
cells, as quantified in bar graphs. The western blots indicate the effect of inducib
DMSO or RA (10 mM), Dox (250 ng/mL), or a combination of RA and Dox.
Unpaired t test. **p < 0.01, ***p < 0.001, and ****p < 0.0001. Quantified data areALKF1174L mutation together with chromosome 2p-gain, and
SK-N-BE(2) harbors MYCN amplification together with a
p53C145F mutation and low NF1 expression. DLG2 expression
in SK-N-AS-DLG2, SH-SY5Y-DLG2, and SK-N-BE(2)-DLG2
cells significantly inhibited cell proliferation in vitro (***p <
0.001, Figures 1G–1I) and induced G1 cell-cycle arrest (Figures
1J and 1K) in NB cells. Thus, in agreement with our hypothesis,
the expression of DLG2 resulted in reduced cell growth.DLG2 Inhibits Tumor Growth In Vivo
An important hallmark of a tumor suppressor is the ability to
inhibit cell division and replication as an anti-oncogene. To
determine whether our in vitro results were relevant in an in vivo
NB model, we implanted SK-N-AS-DLG2 cells and SK-N-AS-
GFP controls in nude mice and monitored tumor xenograft
growth over time. DLG2 expression robustly impaired the growth
of SK-N-AS-DLG2 xenografts relative to SK-N-AS-GFP controls,
with a significant difference between tumorweight and volume at
20 days post-injection (****p < 0.0001, *p < 0.05, Figures 1L and
1M). These results support our initial observations that DLG2
functions as a tumor suppressor in NB cells and are in agreement
with recent observations in osteosarcomas (Shao et al., 2019)
and work in Drosophila (Woods and Bryant, 1991).Ectopic DLG2 Expression Drives Neuronal
Differentiation
We next investigated a role for DLG2 in neuronal differentiation,
using neurite outgrowth as a readout for differentiation. SH-SY-
5Y, SK-N-SH, and SK-N-BE(2) NB cells overexpressing DLG2
displayed increased neurite outgrowth when compared with
GFP controls (Figures 2A–2F and S2). In addition, cells overex-
pressing DLG2 exhibited an upregulation of established
neuronal lineage differentiation markers, such as MAP2A,
NEFH, and TRKA (Cheung et al., 2009; Chu et al., 2003) (Figures
2G–2I and S2).
From a clinical point of view, NB tumors with well-differenti-
ated phenotypes are associated with better prognoses (He
et al., 2017). RA, a differentiation agent, has been shown to
improve event-free survival in high-risk NB patients with minimal
residual disease (Matthay et al., 1999, 2009). Presently, RA is
used as a maintenance therapy in high-risk NB patients (Masetti
et al., 2012). We therefore asked whether DLG2 plays a role in
RA-induced differentiation. The expression of DLG2 in NB cells
induced neuronal differentiation to ~20%, which is comparable
to RA-treated GFP control cells (Figures 2A–2I). However,
DLG2 expression robustly enhanced RA-induced NB differentia-
tion, and >80% of cells differentiated within 24 h compared to
RA-treated controls (Figures 2A–2F). Further analysis revealedpon either DMSO or retinoic acid (RA) (10 mM) treatment for 24 h (for SH-SY5Y
A), SK-N-SH (GFP or DLG2-GFP) (B), and SK-N-BE(2) (GFP or DLG2-GFP) (C).
ing RA treatment.
ssion of neuronal differentiation markers in the indicated NB cells. Asterisk (*)
SH-SY5Y (J and K) and SK-N-BE(2) (L and M) on RA-induced differentiation of
le DLG2 shRNA on DLG2 protein expression upon the treatment of cells with
means ± SDs of at least 3 independent experiments. Scale bar (A–C), 70 mM.
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(Figures 2G–2I). The expression of DLG2 together with RA stim-
ulation induced almost complete differentiation of NB cells, a
level of differentiation response that had not been observed pre-
viously (Kasim et al., 2016; Pandey et al., 2014).
DLG2 Is Required for RA-Induced Differentiation
Since the expression of DLG2 resulted in a robust differentiation
response, we next asked whether the loss of DLG2 would affect
the RA-induced differentiation response. To do this, we gener-
ated stable NB cell lines expressing doxycycline-inducible
DLG2 small hairpin (shRNA). Inducible DLG2 knockdown
resulted in reduced DLG2 protein levels and inhibited RA-medi-
ated neuronal differentiation in both MYCN amplified (SK-N-
BE(2)) and non-MYCN-amplified (SH-SY5Y) cells (Figures 2J–
2M). These results confirm that DLG2 is required for a complete
RA-induced differentiation response in NB cells.
RA Transcriptionally Regulates DLG2 Expression in NB
Cells
To further understand these observations, we examined the ef-
fect of RA treatment on DLG2 in NB cells. RA treatment upregu-
lates DLG2 expression in a time-dependent manner in SH-SY5Y,
SK-N-SH, and SK-N-BE(2) cells (Figures S3A–S3C). Inhibition of
transcription by the addition of actinomycin D blocked RA-
induced DLG2 protein expression in SH-SY5Y cells (Figure S3D),
suggesting that RA regulates DLG2 at the level of transcription.
We confirmed this by qPCR analysis, in which DLG2 mRNA
was similarly upregulated in a time-dependent manner upon
RA treatment (Figure S3E). As a positive control, we used
NTRK1 (encodes TRKA), a previously described bona fide RA
transcription target (Figure S3F) (Lucarelli et al., 1995; von Holst
et al., 1995). Thus, our observations indicate that RA regulates
DLG2 gene expression at the transcriptional level.
DLG2 Overexpression Potentiates NGF-Induced NB Cell
Differentiation
In addition to RA induction of DLG2 levels, we noted an
increased expression of TRKA (Figures S3A–S3C). Our earlier
observations consistently identified upregulated TRKA protein
expression in response to DLG2 expression in NB cells (Fig-
ures 2G–2I, S2B, S2D, and S2F). This was an interesting
observation since low-risk NB patient tumors often exhibit
the characteristic property of spontaneous differentiation
and high TRKA expression levels (Hoehner et al., 1995).
Furthermore, the overexpression of exogenous TRKA en-
hances NGF-induced differentiation in NB cell culture models
(Emdal et al., 2015). Therefore, we examined the effect of NGF
on DLG2-overexpressing cells. DLG2 expression resulted in
the sensitization of NB cells to NGF-mediated morphological
differentiation, increasing the percentage of neurite-bearing
cells in both SH-SY5Y-DLG2 and SK-N-SH-DLG2 cells
compared to their respective controls (Figures S4A–S4D).
Since RA was able to drive DLG2 expression, we also exam-
ined the effect of NGF/TRKA signaling on DLG2 protein levels.
Treatment of SH-SY5Y cells with NGF upregulated endoge-
nous DLG2 protein expression in a time-dependent manner
(Figure S4E). This suggests a positive feedback regulation be-6 Cell Reports 32, 108171, September 22, 2020tween DLG2 and TrkA and further supports DLG2 as an inte-
gral component of the differentiation process.
DLG2 Promotes ADRN Identity in NB Cells
DLG2 expression during differentiation may play a key role in es-
tablishing the identity of neural crest cell and SCP progeny. To
better understand the effect of DLG2 in NB biology, we deter-
mined the downstream transcriptional response of DLG2
expression. Therefore, we performed RNA sequencing (RNA-
seq) and compared differential expression between DLG2-over-
expressing and control SH-SY5Y cells. DLG2 overexpression
resulted in 414 upregulated and 122 downregulated genes (dif-
ferential expression defined at a log fold change (FC) cutoff of
2 at a 1% false discovery rate (FDR; Figure 3A). These differen-
tially expressed genes were enriched for genes involved in
neuronal differentiation (Figure 3B) and included the neuronal
markers NRCAM (log2FC = 2.95), NEFM (log2FC = 2.69), NEFH
(log2FC = 2.33), and ASCL1 (log2FC = 3.85) (Figure 3A; Table
S1). Similar responses were observed at the protein level (Fig-
ure S5; Table S1).
Because our previous results indicated similar neuronal dif-
ferentiation effects between RA treatment and after DLG2
overexpression, we compared the DLG2-induced gene
expression changes with the transcriptional response resulting
from the treatment of SH-SY5Y cells with RA for 24 h. RA
treatment regulated 301 genes, with 83 (27.6%) of these over-
lapping with the response measured after DLG2 overexpres-
sion and including DLG2 itself (log2FC = 2.40; Table S1). The
other genes were regulated by RA only and included RET
(log2FC = 2.43), MYC (log2FC = 3.14), and NTN4 (log2FC =
2.29). The neuronal differentiation markers NRCAM, NEFM,
and NEFH were not significantly affected after RA treatment,
with similar findings again between mRNA and protein levels
(Table S1). Using hierarchical clustering, we identified a set
of 73 genes that was uniquely upregulated by RA and was pre-
dicted to be regulated via the RA receptors RARA and RARB
(cluster 2 in Figure 3C). A larger set of 263 genes was identi-
fied that responded to DLG2 overexpression only and was
predicted to be mediated by other transcription factors
(TFs), such as REST, SMAD1, TBP, and TCF4 (cluster 3 in Fig-
ure 3C). These results identify substantial transcriptional differ-
ences between DLG2-induced and RA-induced differentiation
responses.
Since both ADRN and mesenchymal (MES) cell types have
been reported in NB cells, we compared DLG- or RA-induced
transcriptional responses to a published set of ADRN and
MES signature genes. MES cells are enriched in post-therapy
and relapsed NB tumors, resembling neural crest-derived pre-
cursor cells, which can differentiate into several types (van Gro-
ningen et al., 2017). Analysis of serial bone marrow samples in
high-risk NB patients showed that MESmRNAs increase during
treatment and were highly predictive of relapse (Wezel et al.,
2019). In contrast, ADRN-type cells represent a more differenti-
ated state, with similarities to the ADRN lineage as in chromaffin
cells (van Groningen et al., 2017). ADRN mRNAs decrease dur-
ing the treatment of NB patients, which may indicate the deple-
tion of ADRN cells in the tumor (Wezel et al., 2019). An ADRN
gene enrichment was observed for genes responding to DLG2
Figure 3. RNA-Seq Differential Expression Analysis of DLG2 Overexpression
RNA-seq-based differential gene expression was measured in SH-SY5Y cells after overexpression of DLG2.
(A) Volcano plot with neuronal differentiation markers and ASCL1 labeled in black. DLG2 is also indicated in black. Dashed lines show differential expression
cutoffs (log2FC at 1% FDR).
(B) Gene Ontology (GO) gene set enrichment analysis (GSEA) on 536 differentially expressed genes. Bar plot shows the top 5 enriched GO terms related to
differentiation.
(C) Heatmap comparing differential expression signatures between cells overexpressing DLG2 and/or cells treated with RA for 24 h. Genes that are differentially
expressed in minimal 1 condition are shown. Genes were hierarchically clustered, and the 4 main clusters are colored on the right side of the heatmap. The bar
plot on the right shows the predicted transcription factors (TFs) responsible for each cluster, with indication of enrichment values.
(D) Bar plots indicate enrichments of ADRN (left) and MES (right) marker genes for different conditions, as indicated. *p < 0.05, **p < 0.01, and ***p < 0.001.
(E) MES and ADRN signature scores for cells in control conditions, overexpressing DLG2 and/or treated with RA. Two-headed arrow indicates the 2-dimensional
spatial difference between RA-treated and DLG2-overexpressing cells.
All of the experiments were performed using 4 biological replicates in each condition.
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test), but not for genes responding to RA treatment (p = 0.46;
Figure 3D). A rank percentile-based scoring method has been
suggested based on these gene signatures, in which MES dif-
ferentiation is characterized by higher MES and lower ADRN
scores and vice versa for ADRN differentiation (see van Gronin-
gen et al., 2017 and Method Details). We calculated these
scores for our different experimental conditions and found
ADRN scores after DLG2 overexpression (mean 0.78 versus
0.75 in control conditions, p = 1.2e6, Student’s t test) and
increased MES scores after RA treatment (mean 0.65 versus
0.63 in control conditions, p = 1.9e5) (Figure 3E). In summary,
our differential expression analysis suggested that DLG2
expression results in a strong ADRN differentiation response,
which is different from themoreMESRA-induced differentiation
response (Figures 3C–3E).ALK Suppresses the Expression of DLG2 through the
Mitogen-Activated Protein Kinase (MAPK) Pathway
Recently, we reported a clinical case in which an NB patient car-
rying an ALK-I1171T activating mutation was treated with the
ALK inhibitor ceritinib. On resection after treatment, the residual
primary tumor showed significant differentiation, resembling
ganglioneuroblastoma (Guan et al., 2018). Expression of the hu-
man ALK-F1174Lmutant in mouse neural crest cells significantly
perturbs early sympathetic progenitor differentiation and in-
creases their proliferation (Vivancos Stalin et al., 2019). While
ALK mutations occur in ~10% of NB cases, Chang et al. (2020)
recently reported high ALK protein expression in 41% of NB tu-
mors, in which ~86% of tumors with high ALK or MYCN protein
expression exhibited an undifferentiated or poorly differentiated
histology. These reports highlight a potential effect of ALK
signaling activity in maintaining a poorly differentiated NB state.Cell Reports 32, 108171, September 22, 2020 7
Figure 4. ALK Suppresses the Expression of
DLG2 through the MAPK Pathway
(A–C) Western blot analyses of the effect of time-
dependent ALK inhibition, with lorlatinib (30 nM), on
DLG2 expression in the indicated NB cell lines.
(D and E) qPCR analyses of the effect of lorlatinib
(30 nM) treatment on DLG2 expression levels in the
indicated NB cells.
(F and G) ALK-driven NB cells were treated with
lorlatinib (30 nM), trametinib (10 nM), or BEZ235
(250 nM), and their effect on DLG2 protein levels
determined by western blot analysis, quantified,
and represented as bar graphs below. pAKT and
pERK1/2 were included as readout for downstream
signaling.
Unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001; ns, not significant. Quantified
data are means ± SDs of at least 3 independent
experiments.
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Overall, NB cell lines express very low to undetectable DLG2
protein levels (Figure S6A). Treatment of ALK-dependent NB
cells, such as CLB-GA, CLB-GE, and SH-SY5Y with the ALK
tyrosine kinase inhibitor (TKI) lorlatinib, resulted in time-depen-
dent upregulation of both DLG2 protein (Figures 4A–4C) and
mRNA expression (Figures 4D and 4E). These results suggest
that ALK signaling may transcriptionally repress expression of
DLG2 in NB.
As ALK signals through numerous downstream signaling
pathways, including the MAPK and phosphatidylinositol 3-ki-
nase (PI3K)-AKT pathways, we next determined the pathway
by which ALK regulates DLG2. Inhibition of ERK1/2 down-
stream of ALK, with the MEK1/2 inhibitor (MEKi) trametinib
increased DLG2 protein expression in a manner similar to
that observed for ALK TKI treatment (Figures 4F and 4G). In
agreement, trametinib treatment upregulated DLG2 protein
expression in a time-dependent manner similar to ALK inhibi-8 Cell Reports 32, 108171, September 22, 2020tor (ALKi) treatment (compare Figure S6B
with Figures 4A–4C). In contrast, the inhi-
bition of AKT activity with the PI3K inhib-
itor BEZ235 had no observable effect on
DLG2 protein levels (Figures 4F and 4G).
To highlight the importance of ERK
signaling in the regulation of DLG2
expression, we also investigated the
SK-N-AS (KRASQ61K driven) NB cell line.
As expected, the activation of ERK1/2
was unaffected by treatment with lorlati-
nib, since SK-N-AS is not an ALK-driven
NB cell line. In contrast, the treatment
of SK-N-AS with trametinib effectively
blocked ERK1/2 phosphorylation and
released the suppression of DLG2
expression in a time-dependent manner
(Figures S6C and S6D). These data sug-
gest that activation of the MEK/ERK
signaling cascade, via ALK or otheroncogenic drivers such as KRASQ61K, results in the suppres-
sion of DLG2 expression in NB cells.
SP1 Acts Downstream of ALK-ERK1/2 Signaling to
Repress DLG2 Expression in NB
Having shown that ALK, acting through MAPK pathway
signaling, transcriptionally regulates DLG2 expression, we
reasoned that this regulation may involve a transcriptional acti-
vator or a repressor downstream of ERK1/2. To identify potential
TFs that may bind the DLG2 promoter, we performed an in silico
analysis of chromatin immunoprecipitation (ChIP)-seq data us-
ing the ChIPBase (http://rna.sysu.edu.cn/chipbase) online plat-
form. This identified Specificity Protein 1 (SP1), which is known
to be phosphorylated by ERK1/2, regulating its stability and
DNA-binding properties (Beishline and Azizkhan-Clifford,
2015), as a potential candidate.
To investigate a role for SP1 in the regulation of DLG2 expres-
sion, we treated two ALK-driven NB cell lines with increasing
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sumoylation of SP1 protein by inhibiting SENP1 protease
expression, leading to ubiquitin-mediated degradation of SP1
(Hsu et al., 2012). ALKi and MEKi were included as positive con-
trols. BA treatment led to a decrease in SP1 protein levels as ex-
pected, together with a concomitant increase in DLG2 protein
expression, with no effect on ERK1/2 phosphorylation (Figures
5A, 5B, S7A, and S7B). Treatment with either ALKi or MEKi re-
sulted in the inhibition of ERK1/2 phosphorylation, decreased
SP1 protein levels, and an increase in DLG2 expression, as ex-
pected. These data support a role for SP1 downstream of
ERK1/2, which is consistent with previous reports (Beishline
and Azizkhan-Clifford, 2015). We next used SP1-specific small
interfering RNAs (siRNAs) to reduce SP1 protein levels in 3 inde-
pendent NB cell lines. This resulted in an increase in DLG2 both
at the mRNA and protein levels in all cases (Figures 5C–5G). To
confirm a role for SP1 in the suppression of DLG2 expression
downstream of ALK-ERK1/2, we generated an inducible SP1
NB cell line (SH-SY5Y-SP1flag). The induction of SP1 led to the
repression of DLG2 expression (Figure S8A). Furthermore, SP1
expression blocked both lorlatinib- and trametinib-mediated up-
regulation of DLG2 (Figure S7C).
To determine whether SP1 directly binds to the DLG2 pro-
moter, we designed biotinylated DNA probes containing CHIP-
predicted (http://rna.sysu.edu.cn/chipbase) SP1-binding sites
containing regions of the DLG2 locus (SP1-wt) (Figure 5H) and
random sequence respectively (ctrl), in a DNA pull-down assay.
SP1 was able to bind the SP1-wt probe but not the control probe
(Figures 5I and 5J), while the non-biotinylated SP1-wt probe
effectively competed SP1 binding (Figure 5K). We did not
observe competition when the SP1-binding site was deleted
(SP1-mut). These results suggest that SP1 acts as a transcrip-
tional repressor downstream of the MAPK pathway to suppress
DLG2 expression in NB.
SP1 Knockdown Induces NB Differentiation through
DLG2 Upregulation
Since SP1 represses the expression of DLG2 and DLG2 overex-
pression leads to NB cell differentiation, we asked whether the
loss of SP1 could also affect NB cell differentiation. In keeping
with a role for SP1 in the regulation of DLG2 expression, we
also observed that siRNA-mediated knockdown of SP1 induced
biochemical differentiation in SH-SY5Y, SK-N-SH, and SK-N-
BE(2) NB cell lines as indicated by increased MAP2, NEFH,
TrKA, and RET expression (Figures 6A, 6D, and 6G). Further-
more, SP1 knockdown significantly increased RA-mediated dif-
ferentiation as compared to siRNA controls (siCtrl) (*p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, Figures 6B, 6C, 6E, 6F,
6H, and 6I). In contrast, the overexpression of SP1 inhibited
DLG2 expression and the downregulated expression of neuronal
differentiation markers, and concomitantly inhibited RA-induced
morphological differentiation (Figures S8A and S8B).
Since the loss of SP1 results in the upregulation of DLG2, we
sought to determine whether DLG2 plays an important role in
SP1-siRNA-induced differentiation. To do this, we transfected
SH-SY5Y-shDLG2 cells with either SP1 siRNA (siSP1) or siCtrl
before treatment with doxycycline or RA or both. The treatment
of cells with doxycycline induced shRNA-mediated DLG2knockdown, and resulted in the attenuation of siSP1-induced
differentiation of NB cells both in the absence and presence of
exogenous RA (Figure 6J). Specifically, SP1 knockdown sponta-
neously induced SH-SY5Y-shDLG2 cell differentiation in the
absence of RA, and this was significantly inhibited upon doxycy-
cline-induced DLG2 knockdown (Figure 6J). Our data show that
SP1 negatively regulates DLG2 and that SP1 knockdown en-
hances NB differentiation. From the Asgharzadeh patient cohort
(https://hgserver1.amc.nl:443/), we found an inverse correlation
between SP1 and DLG2 expression (data not shown). In this
cohort, tumors are histologically graded, allowing the examina-
tion of SP1/DLG2 with respect to tumor differentiation status.
DLG2 was more highly expressed in differentiated tumors, in
contrast toSP1, which exhibited expression in tumorswith undif-
ferentiated or poorly differentiated histology (Figures 6K and 6L).
These findings suggest a potential clinical relevance of DLG2
and SP1 as biomarkers for NB tumor prognosis.
Analysis of 11q del Tumors Identifies DLG2 Aberrations
in NB
NB tumor samples (n = 436) were screened by SNP array to
investigate copy-number variants and allelic imbalances on
11q. Deletions involving 11q were identified in 218 of 436 tumors
(detailed in Table S2). Of these, 2 types of chromosome 11 aber-
rations were observed. The first was a relative loss of the entire
chromosome 11 (98/218 tumors, 45%); these tumors predomi-
nantly showed an overall pattern of numerical imbalances. The
second was segmental loss—in other words, partial 11q loss
(120/218 tumors, 55%) (Table S2). No homozygous 11q losses
were observed. Of the 120 tumors with partial 11q del, all except
10 cases had deletions extending from the breakpoint to the q-
terminal of chromosome 11 (Figure 7A).
Chromosome 11q loss and amplification of MYCN constitute
the 2 major NB unfavorable prognosis groups. In general, there
is an inverse correlation between 11q loss and MYCN amplifica-
tion (Care´n et al., 2010; Chen et al., 2004; Guo et al., 1999). How-
ever, in a small group of NB cases, both of these features occur
simultaneously. In the series of 120 NB tumors with segmental
chromosome 11 deletion, we noted that 26 cases had both
MYCN amplification (MNA) and 11q del, while the remaining 94
had 11q del to varying degrees, in the absence of MNA (Fig-
ure 7A; Table S2). In analyzing the chromosome aberration pat-
terns of these 2 NB groups, we noted that cases with 11q del and
MYCN amplification (here denoted 11q del + MNA) and those
with 11q del without MYCN amplification (here called 11q del)
exhibit different 11q del patterns (Figure 7B). Examination of
the SRO (shortest region of overlap of deletions) showed that
the 11q del + MNA subgroup in general displays more distal
11q del breakpoints (SRO ranging from Chr11:105 to 115 Mb
(hg19) from pter), while the 11q del group that lacks MNA has
a more proximal 11q breakpoint pattern (Figures 7A and 7B)
(SRO chr11:85–103 Mb). There are 84 putative candidate genes
in the proximal SRO (chr11:85–103) (hg19) in 11q del NB fromour
patient group (Table S3). DLG2 is the most proximal of the 84
genes, harboring a cluster of breakpoints that potentially disrupt
the DLG2 locus (Figures 7B, S9A, and S9B). A total of 17 of120
clustered from both the 11q del and the 11q del + MNA sub-
group, which display proximal deletion breakpoints either in orCell Reports 32, 108171, September 22, 2020 9
Figure 5. SP1 Acts Downstream of the ALK-ERK1/2 Signaling Axis to Repress DLG2 Expression in NB
(A and B) Western blot analyses of SP1, DLG2, and indicated proteins in whole-cell lysates of SH-SY5Y and CLB-GE NB cell lines treated with betulinic acid (BA),
at increasing concentrations for 24 h.
(C–E) Western blot analysis of the effect of SP1 siRNA on DLG2 expression levels. SH-SY5Y (C), CLB-GA (D), and SK-N-AS (E) were transfected with either
scrambled control (siCtrl) or 2 independent siRNAs targeting SP1. Whole-cell lysates were western blotted for SP1, DLG2, and tubulin as loading control.
(F and G) qPCR analysis of DLG2 mRNA levels in SK-N-AS (F) and CLB-GA (G) transfected with either scrambled control (siCtrl) or siRNA targeting SP1.
(H) Schematic depicting theDLG2 promoter region. Red bars indicate the predicted SP1-bindingmotifs and the 571 bp between black bars indicate the predicted
SP1-binding region used as probe.
(I and J) Nuclear extracts from either SK-N-AS (I) or CLB-GA (J) were incubated for 90 min with biotinylated DNA probes (ctrl versus SP1-wt), and SP1-binding
enrichment was analyzed by western blot, quantified below.
(K) Western blot analysis of the competitive effect of either SP1 (SP1-wt) or SP1 mutant (SP1-mut) non-biotinylated (cold) DNA probes on SP1 protein binding to
the DLG2 promotor probe. Competitor cold DNA probes (15 mg) were incubated with nuclear extract 90 min before the addition of the biotinylated SP1-wt probe.
Unpaired t test. *p < 0.05, **p < 0.01, and ****p < 0.0001. Quantified data are means ± SDs of at least 3 independent experiments.
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OPEN ACCESSin close proximity to theDLG2 gene. Furthermore, within the 11q
del, 12 tumors were found with disrupting tumor-specific rear-
rangements either in or in close proximity to the DLG2 gene (Fig-
ures 7C, S9A, and S9B). Analysis of the expression levels of the
84 candidates in NB tumor material identified 15 genes,
including DLG2, that exhibited a lower expression level in unfa-
vorable NB with significant p values (https://hgserver1.amc.
nl:443/; 1.0e3 to 9.8e–8, Versteeg-88 cohort; Table S3). There-
fore, DLG2 is a strong candidate NB tumor suppressor gene in
the high-risk non-MYCN amplified NB tumors with 11q del,
based on position, high number of breakpoints, and expression
levels in tumors (Figures 7, S9A, and S9B; Table S3). This is in
agreement with our earlier observations (Figures 1B, 6K, and
S1), showing that high DLG2 mRNA expression levels correlate
with better patient prognosis. Moreover, overall survival analysis
of NB patient data from this cohort of 436 NB tumor cases sug-
gests that patients with 11q del NB have a poor prognosis,
similar to the MNA category (Figure 7D). We also observed that
patients with 11q del + MNA, although rare, exhibit the worst
prognostic outcomes (Figure 7D). Thus, our genetic data support
the disruption of the DLG2 gene as a tumor suppressor gene
target of the 11q loss of heterozygosity (LOH) observed in NB.
DISCUSSION
Our present understanding of NB tumorigenesis suggests that
11q loss is acquired in unfavorable late-presenting NB (Care´n
et al., 2010). This analysis of a 436-strong NB patient cohort sup-
ports the poor prognosis of 11q del NB patients, which is com-
parable with the high-risk MYCN-amplified patient group. We
also note that patients harboring both 11q del and MYCN ampli-
fication, although rare, constitute an ultra-high-risk group of NB
patients. Our genomic and experimental analysis supportsDLG2
as a potential tumor suppressor gene mapping within the critical
11q del region that is rearranged or deleted in a subset of high-
risk NB. The 11q chromosomal rearrangements identified here
potentially interfere with DLG2 function by directly disrupting
the normal gene structure or upstream regulatory regions. The
Knudson model for LOH involving tumor suppressor genes sug-
gests that the remaining DLG2 allele in these NB tumors may
harbor deleterious mutations. However, we did not find any
genetic lesions in the remaining DLG2 allele in our cohort, sug-
gesting that gene-dosagemechanisms are involved. Haploinsuf-
ficiency has been shown to contribute to tumor development in a
number of examples, such as p27, Hint1, and Dmp1, where the
remaining intact wild-type allele is insufficient to suppress tumorFigure 6. SP1 Knockdown Induces NB Differentiation
(A, D, and G) Western blot analyses of differentiation markers in SH-SY5Y (A), S
control (siCtrl) or 2 independent siRNAs targeting SP1.
(B, E, and H) Representative images of neurite outgrowth in SH-SY5Y (B), SK-N-
(C, F, and I) Quantification of neurite outgrowth in SH-SY5Y (C), SK-N-SH (F), an
(J) The SH-SY5Y-shDLG2 cell line stably expresses an inducible DLG2 shRNA
indicated. The bar graph shows the effect of Dox-induced DLG2 knockdown on
(K and L) Boxplots showing the correlation between tumor grade (differentiated
samples.
Unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001; ns, not signi
Scale bar (B, E, and H) 70 mM.
12 Cell Reports 32, 108171, September 22, 2020growth (Fero et al., 1998; Inoue et al., 2001; Li et al., 2006). It may
also be the case that losses of additional genetic loci on 11q
contribute in the complex genetic landscape of patient tumors.
For example, many genes coding for proteins in the DNA dam-
age response (e.g., ATM, CHEK1, H2AFX, and MRE11) are
located on 11q, in addition to PHOX2A, CCND1, SDHD, and
CADM1, which have been investigated as 11q candidate loci
(Mlakar et al., 2017).
This work establishes an important function of DLG2 in NB
cell differentiation that is consistent with a tumor suppressor
function, and identifies underlying molecular mechanisms by
which ALK-ERK1/2 activity suppresses DLG2 expression.
These findings are in keeping with single-cell expression data
of the developing murine neural crest, in which DLG2 was
noted to be one of the transition bridge cell genes that are ex-
pressed during the differentiation of precursor cells destined to
become sympathetic neurons or chromaffin cells of the adrenal
medulla (Furlan et al., 2017). By examining the bridge cell genes
in the context of NB patient tumor material, we show that high
expression of late peak time bridge cell genes (i.e., those upre-
gulated over time in this cell population) strongly correlates with
better prognosis. In contrast, high expression of early peak
time bridge cell genes (i.e., those downregulated over time in
this cell population) correlates with poor prognosis. These find-
ings suggest an important role for the bridge cell genes in dif-
ferentiation and suggest that their perturbation likely promotes
NB progression.
Although Dlg has been shown to be a tumor suppressor in
Drosophila and its human homolog DLG2 has also recently
been implicated in osteosarcoma tumorigenesis (Shao et al.,
2019; Woods and Bryant, 1991), a role for DLG2 in NB has not
been investigated. Our initial experiments overexpressing
DLG2 resulted in the inhibition of growth of NB cells in vitro, an
effect that was confirmed in mouse xenografts, in which DLG2
expression robustly reduced tumor burden. The overexpression
of DLG2 also promoted neuronal differentiation to levels similar
to those previously reported for RA-induced differentiation (Ka-
sim et al., 2016; Pandey et al., 2014). To our knowledge RA-
induced differentiation results in an incomplete response in NB
cells, with up to 30% of cells differentiating. Moreover, the un-
derlyingmechanismof differentiation is unclear. One explanation
for these observations was suggested recently by vanGroningen
and colleagues (van Groningen et al., 2017), who showed that
NB is composed of two cell types: MES and ADRN cells. Their
work highlighted the high level of transcriptional plasticity ex-
hibited by NB cells, which is reflected in the ability of MES orK-N-SH (D), and SK-N-BE(2) (G) NB cells, transfected with either scrambled
SH (E), and SK-N-BE(2) (H).
d SK-N-BE(2) (I).
. Cells were transfected with either siCtrl or siRNA targeting SP1 (siSP1), as
SP1 siRNA-mediated differentiation in SH-SY5Y-shDLG2 cells.
or undifferentiated) and DLG2 (K) or SP1 (L) mRNA expression in NB tumor
ficant. Quantified data are means ± SDs of at least 3 independent experiments.
Figure 7. Genetic Analysis of 11q Deletions (11q del) in NB Patients Identifies Breakpoints in DLG2
(A) Summary of SNP array genomic profiles showing deletions on chromosome 11q. The genomic position of the DLG2 locus on chromosome 11 is indicated at
left (red box). Each vertical line represents 1 NB tumor and the deleted region is indicated (scale to the left in megabase distances from pter [the short arm
telomere]). Cases with 11q del and MYCN amplification are denoted MNA+11q; those with 11q del without MYCN amplification are denoted 11q del.
(B and C) Cluster of breakpoints and aberrations on 11q. SNP array data breakpoints in MNA+11q cases (B) and 11q del cases (without MNA) (C).
(D) Kaplan-Maier overall survival analysis of the patient data. Patient data are based on the genomic profiles of 436 NB tumor cases (see Table S2).
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MES cells are resistant to therapy and RA-induced differentiation
in vitro (Arumugam et al., 2009; Naiditch et al., 2015; Piskareva
et al., 2015). In our analyses, we also observe an incomplete dif-
ferentiation response to RA alone. However, the treatment ofDLG2-overexpressing NB cells with either RA or NGF results in
a striking synergistic effect, with 90%–100% of cells undergoing
differentiation. This clearly indicates a role for DLG2 as an inte-
gral component of the differentiation process. The importance
of DLG2 is further highlighted by the finding that RA treatmentCell Reports 32, 108171, September 22, 2020 13
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hibits RA-induced differentiation in NB cells.
An additional intriguing observation arose from our RNA-seq
analyses of NB cells expressing DLG2 in comparison with those
treated with RA. Analyzing these data based on the reported
MES and ADRN signatures (van Groningen et al., 2017) revealed
a clear difference in the ‘‘differentiation’’ responses at the mRNA
level, with DLG2 expression strongly promoting an ADRN signa-
ture, whereas RA treatment promoted a mixed ADRN/MES
signature. NB cells that exhibit a more stringent ADRN identity,
such as DLG2-expressing cells, may represent a more
completely differentiated state, in keeping with the observation
that DLG2 expression appears in the later stages of the recon-
structed differentiation time course of the SCP-chromaffin path
(Furlan et al., 2017). This is in keeping with DLG2’s increasing
the ADRN score of NB cells and potentiating RA-induced neuri-
togenesis. The molecular mechanisms underlying the ability of
DLG2 to regulate transcription during differentiation are un-
known at present, although our RNA-seq results do identify
some interesting differences in comparison with RA-induced dif-
ferentiation. Analysis of RA-induced differentiation identified a
clear RA receptor (RARA/B) signature, which was not observed
in DLG-induced differentiation. Conversely, DLG-induced differ-
entiation appears to involve themodulation of genes by TFs such
as REST, SMAD1, TBP, and TCF4. How DLG2 modulates these
transcriptional changes is unclear, and is an interesting topic for
future investigation.
One implication of these findings is that therapeutic ap-
proaches that result in an increased ADRN score and/or
decrease the MES score of NB tumors could enhance RA-
induced differentiation, which may increase the modest clinical
efficacy of RA therapy. One such preclinical approach is the
silencing of the SP1 transcriptional repressor, which we show
here leads to an increase in DLG2 expression and the induction
of neuritogenesis, and further potentiates the RA-induced differ-
entiation of NB cells. It is known that the expression of the human
ALKF1174L-activated mutant in mouse neural crest cells signifi-
cantly impairs early sympathetic progenitor differentiation and
increases their proliferation (Vivancos Stalin et al., 2019). In addi-
tion, we have previously shown that the treatment of an ALK+ NB
patient with ALKi significantly reduced the primary tumor size
and the resected tumor demonstrated significant differentiation,
resembling ganglioneuroblastoma (Guan et al., 2018). The iden-
tification of DLG2 as a key differentiation component that is
repressed by oncogenic ALK-ERK1/2 signaling provides a
mechanistic link between ALK-driven NB and the inhibition of
the differentiation process. Intuitively, one would suggest
combining MEKi and RA to synergistically promote differentia-
tion; however, MAPK/ERK1/2 is also important in both RA- and
NGF-mediated neuronal differentiation, thereby making the
identification and the precise targeting of the anti-differentiation
signaling axis downstream of ERK1/2 essential. Furthermore,
ALK-dependent NB appears to be less sensitive to MEK inhibi-
tion due to feedback mechanisms that increase the activity of
other proliferation and survival pathways (Umapathy et al.,
2017). While we show here that SP1 acts downstream of ALK-
ERK1/2 signaling axis to block NB differentiation through the
repression of DLG2 expression, further investigation will be14 Cell Reports 32, 108171, September 22, 2020required to clarify therapeutic approaches that will be of benefit
to NB patients.
In summary, our data suggest that an important role for onco-
genic ALK-ERK1/2-SP1 signaling is themaintenance of an undif-
ferentiated state of transformed NC-derived progenitors through
DLG2 repression. The importance of SP1 and DLG2 in this pro-
cess is highlighted by the findings that restoring DLG2 expres-
sion (e.g., by expressing DLG2 or targeting SP1) potently drives
NB differentiation. Furthermore, we show in a clinical cohort of
436 patient tumors that the DLG2 gene genetically maps to a re-
gion on 11q that has a high frequency of aberrations in NB. Our
analysis of DLG2 also suggests that further exploration of other
bridge cell genes may help us to understand the mechanisms
underlying the differentiation of SCPs and SA cells and their
contribution to NB. In this work, we uncover a role for ALK and
other oncogenes driving ERK signaling in NB tumorigenesis.
ALK not only promotes the proliferation and survival of NB cells
but it also suppresses their differentiation by negatively regu-
lating the expression of DLG2, which is frequently deleted in
high-risk NB. The remaining intact DLG2 allele in 11q del NB is
transcriptionally responsive to ALK and ERK pathway inhibition,
leading to increased expression of the DLG2 tumor suppressor
protein. Thus, a subset of 11q del NB may be responsive to
ALK and MEK TKI treatment as a therapeutic option.STAR+METHODS
Detailed methods are provided in the online version of this paper
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Hallberg (bengt.hallberg@gu.se)
Materials Availability
Plasmid generated in this study can be made available upon request to the Lead Contact.
Data and Code Availability
Datasets and codes generated during this study are available at repositories indicated in the Key Resources Table.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture, cell lysis and western blot
All neuroblastoma cell lines were cultured in RPMI-1640medium supplemented with 10% fetal bovine serum (FBS) and 1%penicillin
and streptomycin at 37C, 5% CO2, 95% humidity. CLB-GE, CLB-GA, SK-N-BE(2), SH-SY5Y and SK-N-AS NB cell lines are
described. SH-SY5Y, SK-N-BE(2), SK-N-AS and SK-N-SH were purchased from ATCC. CLB-GE and CLB-GA kindly provided by
Dr. Valerie Combaret, Centre Leon Berard, France. Cells were regularly tested for mycoplasma using Eurofins mycoplasma testing
plateform. Cells were recently authenticated (CLB-GE, CLB-GA and SK-NAS cells) by Tommy Martinsson, described in Umapathy
et al. (2017).
Human patients
Neuroblastoma tumor samples and normal whole blood were collected from Swedish patients after either written or verbal informed
consent was obtained fromparents/guardians according to permits (registration numbers 03/736 and 09/1369) approved by the local
ethics committee at Karolinska Institutet and Karolinska University Hospital.
Mouse models/animals
Female BALB/cAnNRj-Foxn1nu mice (Janvier Labs, France) 4-6 weeks old were group-housed in individually ventilated cages with
access to irradiated standard chow and water ad libitum in a 12:12 light-dark cycle. The mice were randomly assigned to ane3 Cell Reports 32, 108171, September 22, 2020
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OPEN ACCESSexperimental group after 1 week of acclimatization at the facility. All experimental procedures and protocols were performed in
accordance with the Regional Animal Ethics Committee approval, Jordbruksverket (01890-2018).
METHOD DETAILS
Immunoblotting
Cells were seeded, cultured overnight, and then treated for the indicated time points with the indicated inhibitors as outlined in fig-
ures. Whole cell lysates were collected in RIPA lysis buffer. Protein concentration was determined using the Pierce BCA Protein
Assay Kit (Thermo Scientific) prior to boiling at 95C for 5 minutes. Protein samples were subjected to 7.5% or 8.5% SDS polyacryl-
amide gel electrophorysis (PAGE), transferred to polyvinylidene difluoride membranes (Millipore) and immunoblotted with primary
antibodies overnight at 4C. Primary antibodies used, including ALK (Chand et al., 2013), are indicated in each figure. Secondary
antibodies were used at a dilution of 1:5000 and incubated with shaking at room temperature for 1 hour. ECL prime western blotting
detection reagent (Amersham,GE) was used. For endogenous DLG2 blots SuperSignal west femto maximum sensitivity substrate
(Thermo Scientific) was used. Blots were scanned and analyzed using the Odyssey Imaging System and software (LI-COR). The pri-
mary antibodies, inhibitors and other chemicals used are described in the Key Resources Table.
Plasmid cloning and lentivirus
pLenti-DLG2-mGFP and pLenti-mGFP lentiviral particles were purchased from Origene Technologies. SK-N-BE(2). SMARTvector
inducible non-targeting control, shCtrl, DLG2 shRNA; shDLG2 #1and shDLG2 #2 lentiviral particles were purchased from Horizon
and described in the Key Resources Table. SP1(NM_138473.3) ORF cloned into pcDNA3.1 by, and ordered from, Genscript. The
SP1 ORF was then subcloned into pLVX-TRE3G (Takara) lentiviral vector using infusion HD cloning (Takara) to form pLVX-
TRE3G-SP1-c-Flag vector. Lentivirus supernatant was produced in HEK293T cells using pLVX-TRE3G-SP1-c-Flag vector and
Lenti-X Packaging Single Shot reagent Xfect Transfection Reagent premixed with an optimized formulation of Lenti-X lentiviral pack-
aging plasmids (Takara), and manufacturers protocol was followed. NB cell lines were transduced with respective lentiviral particles
and corresponding stables cell lines were established as indicated in the figures. Transduced cells were selected with 1 mg/ml of pu-
romycin to establish stable cell lines.
Cell proliferation, cell cycle and differentiation assays
Cells (6000 – 8000 cells/well) were seeded in triplicates into wells of 96-well plates (Eppendorf) and cultured in RPMI, supplemented
with 10% FBS, overnight at 37C in incucyte S3 (Essen BioScience). Cell growth/proliferation was recorded inside the incucyte by
scanning the cells at 12 hours interval for 5 days. Cell percentage confluency was determined for each scan using incucyte S3 soft-
ware (Essen BioScience). The normalized cell growth data was then imported to Graphpad Prism 7 to plot cell proliferation curves.
The experiment was repeated three independent times.
For cell cycle analyses, cells (2.53 105 cells/well) were seeded and cultured RPMI, supplemented with 10% FBS for 48 hours. The
cells were then harvested and rinsed with PBS, followed by ethanol fixation for 3 hours at 4C. Cell cycle analysis was carried out
using NucleoCounter NC-3000 (Chemometec) and manufacture’s protocol, Fixed-Cell-Cycle-DAPI-Assay, was followed. Briefly,
fixed cells were resuspended in solution 3 DAPI (1 mg/ml DAPI, 0.1% Triton X-100, in PBS) and incubated for 5 minutes at 37C. Cells
were then loaded unto NC-Slide A2 and scanned in NucleoCounter NC-3000. Cell cycle data was analyzed using plot manager in
NucleoView NC-3000 software. Each experiment was repeated three independent times.
For differentiation assays, 50,000 to 60,000 cells were seeded in 6-well plates and cultured overnight and treated with retinoic acid
(RA) (10 mM) or NGF (100 ng/ml) for indicated periods. Doxycycline was added on same day, where needed, when cells were seeded
in 6-well plates, i.e at least 18 hours prior to RA treatment. Cells were considered as differentiated when a neurite projecting from a
cell was at least 1.5 times the size of the cell body. At least 200 cells were counted in at least 4 random fields under microscope and
the number of differentiated cells noted and calculated for percentage differentiation and graphs plotted with graphpad prism. Differ-
entiated cells were photographed using Olympus CK40microscopemounted with Olympus DP12 camera (Olympus Optical, Japan).
Results are mean of at least three independent biological replicates.
RNA extraction and Quantitative PCR
To determine transcriptional responses of DLG2 under different conditions, RNA extraction was done by ReliaPrep RNA Miniprep
Systems (Promega) and cDNA was synthesized by iScript cDNA synthesis kit (Biorad). Quantitative PCR was performed on StepO-
nePlus Real-Time PCRSystems using Power SYBRGreenmastermix and following primers presented in Key Resources Table and
Table S4.
Nuclear extract isolation and DNA probe pulldown assay
Genomic DNAwas extracted from neuroblastoma cell line (SH-SY5Y) using DNAeasy Blood and Tissue kit (QIAGEN). CHIPbase
(http://rna.sysu.edu.cn/chipbase) online tool predicted SP1 binding locus (chr11:85628043..85628782) located within 1 kilobase
pair upstream ofDLG2 transcriptional start site. Biotinylated primers were ordered from Integrated DNA Technologies (IDT, Coraville,
IA). SP1-wt probe (571 bp) spanning the predicted SP1 binding locus (chr11:85628043..85628782), was amplified from the extractedCell Reports 32, 108171, September 22, 2020 e4
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The SP1binding locus was predicted to contain two SP1 motifs and these motifs were deleted in SP1-wt probe to form SP1 mutant
probe (SP1-mut) (506 bp) using non-biotinylated primers. Primers used are outlined in the Key Resources Table.
For nuclear lysate extraction, cells were washed with ice-cold PBS and cell membrane was lysed using cell membrane lysis buffer
A (Cell Signaling Technology) containing protease inhibitor cocktail (Cell Signaling Technology). Lysate was centrifuged at 9000 x g
for 3 minutes at 4 C and nuclear pellet was collected and washed once with 1 mL of buffer A. Nuclear pellet was resuspended in 0.5
to 1 mL buffer B (20mM HEPES, 100 mM KCl, 0.2 mM EDTA, 8% glycerol, pH 7.2) and sonicated on ice for 7 cycles (30 s ON, 40 s
OFF, 100% amplitude) (Sonicator-FB120, Fisher Scientific, PA, USA). Nuclear suspension was centrifuged for 5 mins at 9000 x g and
supernatant was collected and frozen at 80 C. Protein concentration was measured by Pierce BCA protein assay kit (Thermo
Fisher Scientific, Sweden).
For DNA probe pulldown assay, nuclear extract (50 mg to 100 mg) wasmixed with 40 ml DynabeadsMyOne streptavidin C1 (Thermo
Fisher Scientific, Sweden), 4 mg of biotinylated SP1-wt or ctrl DNA probes and diluted with PBS to 500 ml volume, followed by incu-
bation at 4 C for 90 minutes. In competition assay, nuclear extract was incubated with 15 mg of either non-biotinylated SP1-wt or
SP1-mut probes for 2 hours prior to incubation with biotinylated 4 mg SP1-wt probe. Dynabeads were washed at least 5 times
with 1 mL ice-cold PBS, with 5 minutes rotation per wash at 4 C. Thereafter, 60 ml of 2X SDS sample buffer was added to beads,
vortexed and heated at 95 C for 5 minutes. Sample was subjected to PAGE and immunoblotted with SP1 antibody.
Mouse xenografts
Female BALB/cAnNRj-Foxn1numice (Janvier Labs, France) 4-6 weeks old were housedwith access to food and water ad libitum in a
12:12 light-dark cycle. The animals were allowed to acclimatize for 1 week prior to being subcutaneously injected into the left flank
with 2,5 3 106 SK-N-AS-GFP or SK-N-AS-DLG2 cells in serum-free medium mixed with Matrigel Matrix at a ratio of 1:1. The total
injection volume was 100 mL. Tumor size was measured by caliper and the volume calculated by the following equation: V = (p/6)
3 L3W2 (V, volume; p, pi; L, length; W, width). The tumors were excised and weighed at the end of the experiment. All experimental
procedures and protocols were performed in accordance with the Regional Animal Ethics Committee approval, Jordbruksverket
(01890-2018).
RNA-Seq data analysis
RNA-seq reads were aligned to the human GRCh38 reference genome using hisat2 (Kim et al., 2015). The average alignment effi-
ciency was 93.2%. Genes were annotated using GENCODE v29 (Harrow et al., 2012) and quantified using HTSeq (Anders et al.,
2015). Only coding genes were used for further analysis. Differential gene expression was determined using DESeq2 (Love et al.,
2014). Genes were considered differentially expressed if their absolute log2 fold change values were above 2 at false discovery
rate (FDR)-adjusted P values below 0.01.
Differential expression heatmaps were constructed using the R gplots package. Hierarchical clustering was performed using the
complete-linkagemethod and the Euclidean distance function (default settings). Only genes that were differentially expressed inmin-
imal one of the analyzed conditions were considered.
ADRN andMES signature genes were derived from Van Groningen et al. (van Groningen et al., 2017). Within each sample, the rank
percentile of an individual gene’s expression value was used to define a gene score. The ADRN and MES gene signature score was
then defined as the mean gene score of all ADRN and MES signature genes respectively.
A gene set enrichment analysis (GSEA) was performed to find gene ontology (GO) term enrichments and to predict TFs responsible
for the observed differential expression. GSEAwas performed using Fisher’s exact test followed by false discovery rate (FDR) correc-
tion using the Benjamini-Hochberg method (Benjamini and Hochberg, 1995). Gene Ontology (GO) information was downloaded from
the Molecular Signatures Database v6.2 (Subramanian et al., 2005) and transcription factor target information was derived from
RegNetwork (Liu et al., 2015), downloaded from http://www.regnetworkweb.org/. Only TFs that were expressed in the analyzed sam-
ples were considered.
Proteomic Tandem Mass Tag labeling and LC-MS/MS analysis
For proteomic sample preparation, SH-SY5Y-GFP and SH-SY5Y-DLG2 cells were seeded and treated with either DMSO or retinoic
acid (10 mM) for 24 hr. Cells were harvested and washed with PBS. Cell pellets were homogenized using a FastPrep-24 instrument
(MP Biomedicals, https://www.mpbio.com) with Lysing Matrix D for five repeated cycles (speed 6.5 m/s, 40 s/cycle) in 200 ml of the
buffer containing 2% sodium dodecyl sulfate and 50mM triethylammonium bicarbonate (TEAB). Samples were centrifuged at 16
000 g for 10 min and the supernatants were transferred into clean tubes. Protein concentration of the lysates was determined using
Pierce BCA Protein Assay Kit (Thermo Scientific) and the Benchmark Plus microplate reader (BIO-RAD) with bovine serum albumin
(BSA) solutions as standards.
Prior to TMT labeling, samples were digested with trypsin using the filter-aided sample preparation (FASP) method (Wisniewski
et al., 2009). Briefly, 30 ug from each sample was reduced with 100 mM dithiothreitol at 60C for 30 min, transferred to 30 kDa
MWCO Pall Nanosep centrifugation filters (Sigma-Aldrich), washed several times with 8 M urea and once with digestion buffer prior
to alkylation with 10 mM methyl methanethiosulfonate in digestion buffer for 30 min. Digestion was performed in 50 mM TEAB, 1%
sodium deoxycholate (SDC) buffer at 37C by addition of 0.3 mg Pierce MS grade Trypsin (Thermo Fisher Scientific) and incubatede5 Cell Reports 32, 108171, September 22, 2020
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tion, and labeled using TMT 11-plex isobaric mass tagging reagents (Thermo Scientific) according to the manufacturer instructions.
After pooling of the TMT set, SDCwas removed by acidification with 10%TFA. The proteinswere pre-fractionated into 40 fractions by
basic reversed-phase chromatography (bRP-LC) using a Dionex Ultimate 3000 UPLC system (Thermo Fisher Scientific). Peptide
separation was performed using a reversed-phase XBridge BEH C18 column (3.5 mm, 3.0x150 mm,Waters Corporation) and a linear
gradient from 3% to 40% acetonitrile in 10 mM ammonium formate buffer at pH 10.00 over 17 min, followed by an increase to 90%
acetonitrile over 5 min. The fractions were concatenated into 20 fractions, dried and reconstituted in 3% acetonitrile, 0.2% formic
acid.
For LC-MS/MS analysis, peptide fractions were analyzed on an Orbitrap Fusion Tribrid mass spectrometer interfaced with Easy-
nLC1200 liquid chromatography system (both Thermo Fisher Scientific). Peptides were trapped on an Acclaim Pepmap 100 C18 trap
column (100 mmx 2 cm, particle size 5 mm, Thermo Fisher Scientific) and separated on an in-house packed analytical column (75 mmx
30 cm, particle size 3 mm,Reprosil-Pur C18, Dr.Maisch) using a linear gradient from 5% to 35%Bover 75min followed by an increase
to 100%B for 5 min, and 100%B for 10 min at a flow of 300 nL/min. Solvent A was 0.2% formic acid in water and solvent B was 80%
acetonitrile, 0.2% formic acid. MS scans were performed at a resolution of 120,000, m/z range 380-1380. MS/MS analysis was per-
formed data-dependent, with top speed cycle of 3 s for the most intense doubly or multiply charged precursor ions. Most intense
precursors were fragmented in MS2 by collision induced dissociation (CID) at a collision energy of 35 with a maximum injection
time of 50 ms, and detected in the ion trap followed by multinotch (simultaneous) isolation of the top 10 MS2 fragment ions, with
m/z 400-1400, selected for fragmentation (MS3) by higher-energy collision dissociation (HCD) at 65% and detection in the Orbitrap
at a resolution of 50,000 and m/z range of 100-500. Precursors were isolated in the quadrupole with an isolation window of 0.7 m/z
and a dynamic exclusion within 10 ppm during 60 s was used for m/z-values already selected for fragmentation.
The data files for the TMT set were merged for identification and relative quantification using Proteome Discoverer version 2.2
(Thermo Fisher Scientific). The search was performed by matching against the Homo sapiens Swissprot Database (version
November 2017, Swiss Institute of Bioinformatics, Switzerland) using Mascot 2.5 (Matrix Science) with a precursor mass tolerance
of 5 ppm and fragment mass tolerance of 0.6 Da. Tryptic peptides were accepted with zero missed cleavage, variable modifications
ofmethionine oxidation and fixed cysteine alkylation; TMT-label modifications of N-terminal and lysine were selected. Percolator was
used for the validation of identified proteins and the quantified proteins were filtered at 1% FDR and grouped by sharing the same
sequences to minimize redundancy. TMT reporter ions were identified in the MS3 HCD spectra with 3 mmumass tolerance, and the
TMT reporter intensity values for each sample were normalized on the total peptide amount. Only peptides unique for a given protein
were considered for quantification.
Differential protein expression was determined using the R ROTS package (Love et al., 2014; Suomi et al., 2017). Proteins were
considered differentially expressed if their absolute log2 fold change values were above 1 at false FDR-adjusted P values below 0.01.
SNP microarray analysis and whole genome sequencing
Genomic profiling on human NB tumors was performed with high density Affymetrix single nucleotide polymorphism (SNP) micro-
arrays as described earlier (Care´n et al., 2010). For primary data analysis, the GDAS software (Affymetrix) was used while genomic
profiles and determination of amplicon boundaries were performed using either Chromosome Analysis Suite (ChAS) (Affymetrix) or
Copy Number Analyzer for Affymetrix GeneChipMapping arrays (CNAG 3.0) (Nannya et al., 2005). The genomic position of endpoints
was determined as the position of the first marker located outside of the amplified region according the UCSC hg19 assembly.
Whole genome sequencing (WGS) was performed on tumor DNA and corresponding constitutional DNA extracted from blood for 8
neuroblastoma patients with intragenic DLG2 aberrations aiming for at least an average coverage of 60X for tumor libraries and 30X
for constitutional DNA using Illumina instrumentation (Illumina, San Diego, CA, USA) at Clinical Genomics, SciLife Laboratories,
Stockholm, Sweden. Mapping to the human reference genome hg19, removal of read duplicates, realignment around InDels and
basescore-recalibration and variant calling was carried out using the Sentieon suite of bioinformatics tools (Sentieon Inc, Mountain
View, CA). The Canvas tool (version 1.38.0.1554) (Roller et al., 2016) was used to call copy number alterations (CNA), where gains and
losses of genomic regions as well as LOH-regions were identified using read depth coverage in combination with SNV b-allele fre-
quencies. For calling of germline and somatic CNVs the SmallPedigree-WGS and Somatic-WGS algorithms of Canvas was used
respectively. Calling of somatic structural variants (SV) were done using the Manta tool (version 1.1.1) (Chen et al., 2016) that applies
information of soft clipped read ends, disjointed read-pairs and read-pair orientation for identification of larger structural variation
(deletions, duplications, inversions and translocations). Calls from the constitutional DNAwere supplied to filter out germline variation
and artifacts caused by problematic regions, in addition, further filtering and removal were also done based on presence in the Swe-
Gen Variant Frequency dataset (https://swefreq.nbis.se/) or in our in-house set of normal controls.
QUANTIFICATION AND STATISTICAL ANALYSIS
Graphs were generated and statistical analysis was performed using GraphPad Prism 8.01 or the R statistical package (v. 3.5). West-
ern blots were quantified using Image studio lite software (LI-COR). The number of biological replicates, (at least n = 3), are indicated
in each figure. Details on the statistical tests used in this study are reported in the respective sections and figure captions.Cell Reports 32, 108171, September 22, 2020 e6
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Figure S1. Related to Figure 1C. Low DLG2 gene expression correlates with poor survival probability in NB. 
Expression data from four different publically available NB tumor data sets (Kocak, Versteeg, SEQC and Oberthuer) derived 
from the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) show that low DLG2 expression levels correlate 
with poor overall and eventfree survival using both (A) Kaplan-scan method and (B) Median scan for cutoff.
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Figure S2. Related to Figure 1I and 2. DLG2 overexpression induces spontaneous differentiation of NB cells.(A,C,E), 
Representative images showing morphological differentiation of NB cells. (B,D,F), Western blot showing increased expression of 
neuronal differentiation markers in NB cells with DLG2 overexpression. * denotes the endogenous DLG2 protein. Scale bar, 70µM
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Figure S3. Related to Figure 2. Retinoic acid regulates DLG2 expression at the transcriptional level in NB cells.
(A-C) Western blot analysis showing effect of RA (10 µM) on DLG2 and the indicated protein expression levels. (D) Western blot analysis 
of the effect of actinomycin D (ActD) on RA-induced DLG2 protein expression in SH-SY5Y cells. qPCR analysis of the effect of RA on 
DLG2 (E) and NTRK1 (F) mRNA expression in SH-SY5Y cells. Unpaired t-test *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
Quantified data are means +/- SD of at least three independent experiments.
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Figure S5. Related to Figure 3. Proteomics analysis after DLG2 overexpression.
Proteomics based differential protein expression was measured in SH-SY5Y cells after overexpression of DLG2. (A) Vulcano plot with 
several neuronal differentiation markers indicated in red. DLG2 indicated in black. Dashed lines show differential expression cut-offs.
(B) Heatmap comparing differential expression protein signatures between cells overexpressing DLG2 and/or cells treated with RA for
24h. Only proteins that are differentially expressed in minimal 1 condition are shown. Proteins were hierarchically clustered, and the 4
main clusters are coloured on the right side of the heatmap.
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Figure S6. Related to Figure 4. MAPK/ERK1/2 pathway suppresses DLG2 expression in NB.
(A) Western blot showing DLG2 protein expression in a panel of different NB cell lines. (B) Western blot showing the effect of
the MEK inhibitor (trametinib) on ALK-addicted NB cell line (SH-SY5Y). (C) The effect of trametinib on ALK-wild type NB
cell line (SK-N-AS). (D) The SK-N-AS (ALK-wt and NRAS-mut) NB cell line was treated for 24 hrs with either trametinib
(10nM), lorlatinib (30 nM) or BEZ235 (250nM)(PI3Ki). Cell lysates were analyzed by western blot as indicated.
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Figure S7 . Related to Figure 5. ALK-ERK1/2-SP1 signaling suppresses DLG2 expression in NB.
SH-SY5Y cells were treated with (A) ALK inhibitor, lorlatinib or (B) with MEK1/2 inhibitor, trametinib, at indicated time points 
and whole protein lysates analysed by western blot. (C) SH-SY5Y-SP1-c-flag is a SP1-c-flag doxycline (dox) inducible stable cell 
line. Cells were treated with dox (1 µg/ml) as indicated 24 hours prior to treatment of cells with lorlatinib (100 nM) or trametinib 
(10 nM) or in combination with dox for additional 24 hours. Cell lysates were collected and subjected to western blot analysis as 
indicated. DLG2 bands were quantified and normalised to total ERK and to non-treated control, band intentsities are indicated 
below the DLG2 blot.
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Figure S8 . Related to Figure 6. Inducible expression of SP1 suppresses expression of DLG2 and neuronal markers, and 
inhibits differentiation. SH-SY5Y-Tet-SP1-c-flag (SH-SY5Y-SP1-c-flag) is a stable doxycycline (dox) inducible SP1 
overexpression SH-SY5Y cell line. (A) SP1 expression was induced with dox (1µg/ml) for 48 hrs and cell lysate subjected to 
western blot analysis to determine SP1 expression and effect on neuronal differentiation markers. (B) SP1 expression was induced 
with dox (0.5 µg/ml) 24 hrs prior to treatment with RA (10 µM). Differentiated cells were counted after 24 hrs of treatment with 
RA and 48 hrs of dox treatment. Experiment is mean +/- SD of three indpendent experiments.
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Figure S9. Related to Figure 7. Intragenic structural 
variations in DLG2.
(A) Coverage profiles from whole genome sequencing data 
showing seven neuroblastoma cases displaying rearrangments 
within DLG2. Translocation fusion sites are specified next to 
arrows. (B) Verification of selected breakpoints through Sanger 
sequencing. Electropherogram in yellow indicates region 
upstream of breakpoint, blue indicates region downstream of 
breakpoint, grey indicates region of microhomology (i.e shared at 
both sites of fusion) while electropherogram in red indicates 
insertion of bases at point of fusion.
Table S2.  Genome profile of the 436 tumors analyzed. Related Figure 7. 
Group Cases, (n) 
MNA 93 
MNA + 11q-del 26 
11q-del 94 
17-gain (no MNA, no 11q-del 52 
Other segmental aberrations 51 
Numerical only (whole chromosome loss and/or gain only 117 
Total 436 
Suppl. Table 3. Genes in the 11q-del consensus region and their expresson vs. Outcome information in the R2 datase. Related to Figure 7. t.
Survival mode:
Cutoff mode:
GENE NAME Kaplan Meier by 
gene expression 
no subset 
p_value Kaplan Meier by 
gene expression 
mycn_amp-no 
subset
p_value Kaplan Meier by 
gene expression 
no subset 
p_value Kaplan Meier by 
gene expression 
mycn_amp-no 
subset
p_value
DLG2 low is worse p=9.8e-08 low is worse p=8.0e-08 low is worse p=1.4e-03 low is worse p=0.020a
TMEM126 low is worse p=0.066 low is worse p=0.066 low is worse p=0.882 low is worse p=0.122
CREBZF low is worse p=3.6e-04 low is worse p=2.7e-09 low is worse p=4.8e-03 low is worse p=8.4e-04
CCDC89 low is worse p=0.142 high is worse p=0.080 low is worse p=0.625 low is worse p=0.574
SYTL2 low is worse p=8.3e-03 low is worse p=0.018 low is worse p=0.226 low is worse p=0.038
CCDC83 high is worse p=0.096 high is worse p=0.180 low is worse p=0.644 high is worse p=0.962
C11orf73 low is worse p=0.217 low is worse p=0.017 low is worse p=0.967 low is worse p=0.102
CCDC81 high is worse p=0.044 high is worse p=0.149 high is worse p=0.488 high is worse p=0.443
PRSS23 high is worse p=5.3e-03 high is worse p=0.024 high is worse p=0.301 high is worse p=0.193
TMEM135 low is worse p=0.045 high is worse p=0.160 low is worse p=0.075 high is worse p=0.258
RAB38 low is worse p=0.051 low is worse p=0.076 low is worse p=0.867 low is worse p=0.664
CTSC low is worse p=0.015 high is worse p=0.027 high is worse p=0.091 high is worse p=0.321
GRM5 high is worse p=0.047 low is worse p=0.112 high is worse p=0.796 low is worse p=0.117
FOLH1B(11q) high is worse p=0.133 high is worse p=0.126 low is worse p=0.685 low is worse p=0.986
FOLH1(11p) high is worse p=0.050 high is worse p=0.047 high is worse p=0.573 high is worse p=0.244
NAALAD2 low is worse p=5.0e-03 low is worse p=9.1e-05 low is worse p=0.022 low is worse p=5.6e-04
CHORDC1 high is worse p=4.8e-03 low is worse p=0.127 high is worse p=0.101 low is worse p=0.388
FAT3 low is worse p=0.038 low is worse p=0.025 low is worse p=0.411 low is worse p=0.109
MTNR1B high is worse p=0.024 high is worse p=0.018 high is worse p=0.085 high is worse p=0.026
SLC36A4 low is worse p=1.9e-03 low is worse p=3.5e-03 low is worse p=3.4e-03 low is worse p=0.038
CCDC67 high is worse p=0.024 low is worse p=0.077 high is worse p=0.036 high is worse p=0.196
C11orf75 high is worse p=0.088 high is worse p=0.171 high is worse p=0.495 high is worse p=0.947
KIAA1731 low is worse p=0.049 low is worse p=8.2e-04 high is worse p=0.317 low is worse p=0.293
TAF1D high is worse p=3.1e-09 low is worse p=1.9e-03 high is worse p=0.041 low is worse p=0.367
C11orf54 low is worse p=1.0e-04 low is worse p=8.6e-10 low is worse p=0.163 low is worse p=6.4e-05
MED17 high is worse p=0.041 low is worse p=2.6e-04 low is worse p=0.847 low is worse p=4.4e-04
PANX1 low is worse p=0.060 low is worse p=7.7e-03 low is worse p=0.739 low is worse p=0.719
GPR83 low is worse p=0.075 low is worse p=0.074 low is worse p=0.218 low is worse p=0.307
ANKRD49 low is worse p=2.1e-04 low is worse p=4.3e-07 low is worse p=0.022 low is worse p=1.2e-04
LOC643037 high is worse p=0.025 low is worse p=0.054 low is worse p=0.965 low is worse p=0.958
FUT4 high is worse p=0.013 high is worse p=0.050 high is worse p=0.396 high is worse p=0.491
PIWIL4 high is worse p=5.9e-03 high is worse p=0.029 high is worse p=0.421 high is worse p=0.522
AMOTL1 low is worse p=0.030 low is worse p=1.1e-03 low is worse p=0.588 low is worse p=0.086
Cutoff_modus: medianCutoff_modus: scan
Overall
CWC15 low is worse p=0.030 low is worse p=3.8e-04 high is worse p=0.998 low is worse p=0.031
KDM4D high is worse p=1.7e-03 high is worse p=6.3e-03 high is worse p=0.012 high is worse p=0.665
SRSF8 low is worse p=3.8e-03 low is worse p=2.5e-06 low is worse p=0.450 low is worse p=0.304
ENDOD1 low is worse p=0.017 low is worse p=1.1e-03 low is worse p=0.033 low is worse p=0.128
SESN3 low is worse p=3.7e-06 low is worse p=2.7e-03 low is worse p=0.024 low is worse p=0.262
FAM76B low is worse p=2.1e-06 low is worse p=2.2e-11 low is worse p=0.062 low is worse p=4.8e-04
CEP57 low is worse p=4.0e-06 low is worse p=6.3e-11 low is worse p=0.376 low is worse p=1.0e-03
MTMR2 high is worse p=4.6e-03 low is worse p=0.015 high is worse p=0.304 low is worse p=0.135
MAML2 high is worse p=0.097 low is worse p=0.163 high is worse p=0.898 low is worse p=0.344
CCDC82 low is worse p=5.5e-07 low is worse p=1.6e-06 low is worse p=6.0e-05 low is worse p=8.2e-04
JRKL low is worse p=1.0e-03 low is worse p=2.0e-05 low is worse p=0.035 low is worse p=8.6e-03
CNTN5 low is worse p=9.6e-03 low is worse p=2.8e-04 low is worse p=0.072 low is worse p=3.3e-03
ARHGAP42 low is worse p=0.264 low is worse p=0.101 low is worse p=0.983 low is worse p=0.618
TMEM133 low is worse p=0.220 low is worse p=0.053 low is worse p=0.273 low is worse p=0.243
PGR high is worse p=0.146 high is worse p=0.129 high is worse p=0.281 high is worse p=0.500
TRPC6 high is worse p=0.031 high is worse p=0.012 high is worse p=0.950 high is worse p=0.886
KIAA1377 low is worse p=2.0e-07 low is worse p=2.7e-07 low is worse p=1.8e-04 low is worse p=3.7e-05
C11orf70 high is worse p=0.049 high is worse p=0.031 low is worse p=0.901 high is worse p=0.624
YAP1 low is worse p=0.154 high is worse p=0.097 high is worse p=0.937 low is worse p=0.667
BIRC3 low is worse p=0.016 high is worse p=0.072 low is worse p=0.486 high is worse p=0.128
BIRC2 low is worse p=2.6e-10 low is worse p=1.5e-10 low is worse p=8.5e-09 low is worse p=7.6e-05
TMEM123 low is worse p=0.054 low is worse p=1.5e-03 low is worse p=0.147 low is worse p=3.6e-03
MMP7 low is worse p=0.050 high is worse p=0.027 high is worse p=0.395 high is worse p=0.108
MMP20 high is worse p=0.082 high is worse p=0.013 high is worse p=0.151 high is worse p=0.342
MMP27 low is worse p=0.111 low is worse p=0.100 low is worse p=0.479 low is worse p=0.653
MMP8 low is worse p=0.108 high is worse p=0.021 high is worse p=0.883 high is worse p=0.124
MMP10 low is worse p=0.279 low is worse p=0.075 high is worse p=0.547 low is worse p=0.634
MMP1 high is worse p=1.4e-08 high is worse p=3.6e-11 high is worse p=1.3e-03 high is worse p=0.019
MMP3 high is worse p=0.035 high is worse p=0.045 high is worse p=0.286 high is worse p=0.181
MMP12 high is worse p=5.5e-04 high is worse p=4.9e-05 high is worse p=0.118 high is worse p=2.7e-03
MMP13 low is worse p=5.7e-03 low is worse p=7.1e-03 high is worse p=0.798 high is worse p=0.902
DCUN1D5 high is worse p=8.1e-04 low is worse p=0.038 high is worse p=0.145 low is worse p=0.371
DYNC2H1b low is worse p=0.011 low is worse p=1.7e-04 low is worse p=0.207 low is worse p=5.0e-03
a Genes consistantly showin "low expression is worse" with a p-value lower than 1.0e-03 are indicated by orange color
b 18 genes or gene like structures were not present in the R2 database
Table S4. Supplemental Primer Table. Related to STAR Methods, sections, Nuclear 
Extraction isolation and qPCR.
Primers Source Identifier 
SP1-mut: forward_1: 
GCTGGTCCGGGGTTTGGA 
This paper N/A 
SP1-mut: forward_2: 
AATCGAGAGGCGGTTGAGCC 
This paper N/A 
SP1-mut: revers_1: 
TACCACTTCGGATTTCCGCCTA 
This paper N/A 
SP1-mut: revers_2: 
CTCGATTGCGTCTAGAAATTACGGC 
This paper N/A 
beta-Actin: forward: 
ATGACCCAGATCATGTTTGAGAC 
This paper N/A 
beta-Actin: forward: 
ATGACCCAGATCATGTTTGAGAC 
This paper N/A 
Primer: SP1-Ctrl probe 
reverse: /Biosg/TGATACACTCTCATCATG
CAGCACATC  
This paper N/A 
Taqman probe_DLG2 Cat# 
Hs00265843_m1_DLG2 
Applied 
Bioscience 
Taqman probe _NTRK1 (TrkA) Ca#Hs01021011_m1_NT
RK1 
Applied 
Bioscience 
Taqman probe_ACTB Cat# 
Hs99999903_m1_ACTB 
Applied 
Bioscience 
